LEARNING FROM ERROR - WHO
Vincristine: what went wrong? Vincristine, a widely used chemotherapeutic agent, should only be administered intravenously and never by any other route. Many patients receiving intravenous vincristine also receive other medication via a spinal route as part of their treatment protocol. This has led to errors where vincristine has
Download LEARNING FROM ERROR - WHO
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
DRUG NAME: Mitomycin
www.bccancer.bc.cavincristine have been beneficial in some patients. 1: Mitomycin BC Cancer Drug Manual ...
NSSG Chemotherapy Protocol
nssg.oxford-haematology.org.ukINPATIENT regimen (Etoposide/ Doxorubicin/ Vincristine ) ETOPOSIDE IV infusion in 500 mL sodium chloride 0.9% over 24 hours. Replace bag promptly daily for a continuous infusion over 96 hours. DOXORUBICIN and VINCRISTINE are mixed together, made up to 48 mL with sodium chloride 0.9% IV infusion and administered via a LV infusor over 96 hours.
R-CHOP-21 / CHOP-21 - NSSG - Haematology
nssg.oxford-haematology.org.uk* Vincristine 1 mg in patients over 70 years of age. Pretreatment with steroids: Some older patients may benefit from a steroid pre-phase consisting of 7 days of oral prednisolone at a dose of 50-100 mg daily. G-CSF primary prophylaxis: Consider for all patients from day 6 for 5 or 7 days. CYCLE FREQUENCY Cycle repeats every 21 days. RESTAGING
BC Cancer Protocol Summary for Treatment of Lymphoma …
www.bccancer.bc.caBC Cancer Protocol Summary LYCHOPR Page 1 of 5 Activated: 5 Mar 2001 Revised: 1 June 2021 (IV bag size clarified) Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment.
PRINCIPLES OF CHEMOTHERAPY IN CANCER
oncologypro.esmo.orgVincristine Vinblastine Vinorelbine Mechanism of action: Bind to microtubular proteins, thus inhibit microtubule assembly resulting in dissolution of the mitotic assembly structure. M- phase specific drugs. Eribulin (Non-taxane tubulin binding agent A marine sponge product)
University of Wisconsin – Madison Lymphoma CHOP-19 …
uwveterinarycare.wisc.eduIf in complete remission at week 19, all therapy stops and monthly re-evaluations are instituted. Total Doxorubicin dose to date: ______ mg _______ mg/m 2
PRESERVATIVE FREE SOLUTION
www.accessdata.fda.govVincristine Sulfate, USP is a white to off–white powder. It is soluble in methanol, freely soluble in water, but only slightly soluble in 95% ethanol. In 98% ethanol, Vincristine Sulfate, USP has an ultraviolet . Vincristine Sulfate Injection, USP is a sterile, preservative–free, single use only solution available for
(*riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRIStine ...
www.hse.ieConsider vinCRIStine dose reduction in elderly patients. Haematological: Table 2: Dose modification in haematological toxicity ANC (x10 9 /L) Platelets (x10 9 /L) Dose < 1 and/or < 75 Delay treatment until recovery. Consider treatment delay and/or adding G-CSF. Renal and Hepatic Impairment:
2020-2021 ISMP Targeted Medication Safety Best Practices ...
www.ismp.orgDispense vinCRIStine and other vinca alkaloids in a minibag of a compatible solution and not in a syringe. Rationale: The goal of this Best Practice is to ensure that vinca alkaloids are only administered by the intravenous route. Vinca alkaloids (vinBLAStine, vinorelbine, vinCRIStine,